About this trial
Despite major advances in therapy and management, HIV/AIDS continues to be a major cause of infectious disease morbidity and mortality on a global scale. The discovery of effective antiretroviral treatment has turned HIV infection into a manageable chronic disease in most patients with access to care. However, the different economic and epidemiologic situation in developing and developed countries requires different research priorities, so that three main challanges are universal and in focus of research of the DZIF HIV Translational Platform:
* Prevention of HIV infection * Long-term life with HIV * HIV cure
The "Translation Reserach HIV" will bring together clinical researchers in HIV infection in order to develop new treatment options to the above mentioned main challanges. It will take advantage of existing expertise (e.g. basic science, novel targets for treatment and HIV eradiation) of the partner sites. This platform is necessary because Germany's HIV research has suffered in the past from a lack of integration between its excellent basic science and clinical research. In addition, there was too little integration into networks that address the main international challenges. There is an urgent need to link these research strands through dedicated structures emphasising the translation of preclinical results into new therapies.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
HIV positive
Disqualifiers
None
Trial population
Patients HIV positive and who are treated in one of the six partner sites
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
9
Trial groupsSee each trial group below.
Trial outcomes
Primary outcomes
Incidence of new HIV infections in Germany
Overall long-term goal of the platform is to develop a translation strategy for the preclinical results concerning HIV prevention from all German research groups with outstanding expertise. Specific outcome measures will be detailed in future subprojects.
Secondary outcomes
Incidence of chronic organ failure and malignant diseases in HIV infected patients
Overall long-term goal of this platform is to focus on co-infections, organ damage and malignant diseases. Research on identifying new correlates of protection and long term viral control will contribute to improved management of HIV infection. Specific outcome measures will be detailed in future subprojects.
Other outcomes
Sustained viral response rate 12 months after discontinuation of ART
Overall long-term goal of this platform is to eliminate silently infected cells or the HIV genomes integrated in these cells. These approaches are currently mostly at the stage of basic research or early preclinical development and need to be developed in the translational chain. Specific outcome measures will be detailed in future subprojects.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital of Cologne
Lead sponsor
German Center for Infection Research
Collaborator
German Federal Ministry of Education and Research
Collaborator